APON(SZ:300753)2025-12-25 08:20Group 1: Company Overview - Aipeng Medical focuses on medical devices, particularly in pain management and upper airway management, while also exploring brain-computer interface (BCI) innovations [3] - The company has a strategic partnership with Ruishen'an Medical, a leading player in the domestic neuroregulation field [3] Group 2: Product Registration and Classification - The company has obtained three Class III medical device registration certificates for its perioperative brain state monitoring product [6] - The multi-modal ADHD behavior training system includes two Class II medical device registration certificates for its hospital and home versions [6] Group 3: Pricing and Reimbursement - The non-invasive BCI adaptation fee is set at 966 RMB per session in regions like Hubei, Zhejiang, and Jiangsu [7] - New regulations from the National Medical Insurance Administration have established a "green channel" for innovative medical products, including BCIs, to expedite clinical practice and application [7] Group 4: Technology and Market Strategy - The company prioritizes the commercialization of non-invasive BCI technologies while considering the strategic integration of high-barrier invasive technologies [5] - The company’s product offerings include a comprehensive system for treating stubborn insomnia, which integrates diagnostic, treatment, and monitoring solutions [8][9] Group 5: Commercialization and Research Initiatives - The ADM series anesthesia depth monitoring products have been launched, but revenue remains modest [10] - Aipeng Medical has established an AI and BCI research institute to drive technological innovation and clinical application in pain management, anesthesia, and mental health [10]